Daiichi Sankyo sinks to massive loss on Ranbaxy woes
This article was originally published in Scrip
Executive Summary
When it reported its third-quarter results in January, Daiichi Sankyo forecast a group net loss of ¥316.0 billion for the fiscal year, stemming from a massive write-down of goodwill for its acquisition of Ranbaxy.